PAREXEL and National Taiwan University Hospital Enter Partnership
to Support Clinical Research in Taiwan
BOSTON and TAIPEI CITY,
Taiwan, Nov. 27, 2012
/PRNewswire/ -- PAREXEL International Corporation (NASDAQ:
PRXL) a leading global biopharmaceutical services provider, and the
National Taiwan University Hospital (NTUH) announced today that
they have established an alliance. Under the agreement, PAREXEL and
NTUH will collaborate to provide drug development services in
Taiwan.
"Partnering with National Taiwan University Hospital further
enhances our ability to meet the increasing demand from our clients
to provide a full scope of Phase I-IV clinical trials in a rapidly
growing market," said Joe Avellone,
M.D., Corporate Senior Vice President, Clinical Research Services,
PAREXEL International. "The National Taiwan University Hospital is
well-known and highly respected in Taiwan. We are pleased to have the opportunity
to work together to advance our biopharmaceutical clients' programs
in the region and help them to compete more effectively in the
global marketplace."
"We are delighted to collaborate with PAREXEL, a world-leading
biopharmaceutical services provider" said
Ming-Fong Chen,
M.D., Ph.D., Superintendent at National Taiwan University Hospital.
"PAREXEL has a wealth of experience in both local and global
clinical development programs. This partnership will bring
opportunities for both PAREXEL and NTUH to leverage our combined
expertise in order to accelerate clinical development programs in
Taiwan and meet patients' need for
more effective treatments."
The alliance will drive greater efficiency for biopharmaceutical
sponsors worldwide. As a center of excellence for clinical trials
in Taiwan and the Asia-Pacific region, the National Taiwan
University Hospital is ideally positioned to support PAREXEL in
delivering a superior clinical development service to local and
global biopharmaceutical companies. The combined experience and
development expertise of the two organizations will help to create
innovative solutions for biopharmaceutical companies looking to
develop or market their products within this important region.
About National Taiwan University Hospital (NTUH)
NTUH started operations in 1895. NTUH's modern hospital was
designed to support the concept of "patient-centered-care", by
which treatment is delivered at the bedside whenever possible. The
hospital endeavors to provide appropriate, effective, and
compassionate care that is accessible, affordable, and culturally
sensitive, and in all these respects it serves as a model to
emulate for other hospitals and clinics across the nation. With
more than 4,000 employees serving approximately 2,000 inpatient
beds, 7,000 daily outpatient visits, and over 200 chemotherapy
treatments per day, NTUH remains the best-known and highest-quality
academic medical center in Taiwan.
For more information, please visit
http://www.ntuh.gov.tw/en/default.aspx.
About PAREXEL International
PAREXEL International Corporation is a leading global
bio/pharmaceutical services organization, providing a broad range
of knowledge-based contract research, consulting, and medical
communications services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. Perceptive
Informatics, Inc., a subsidiary of PAREXEL, provides advanced
technology solutions, including medical imaging, to facilitate the
clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70
locations throughout 51 countries around the world, and has
approximately 13,330 employees. For more information about PAREXEL
International visit www.parexel.com.
This release contains "forward-looking" statements regarding
future results and events, including, without limitation,
statements regarding expected financial results, future growth and
customer demand. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "will," "would,"
"could," "should," "targets," and similar expressions are
also intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of
risks and uncertainties. The Company's actual future results
may differ significantly from the results discussed in the
forward-looking statements contained in this release.
Important factors that might cause such a difference include, but
are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating
improvements resulting from recent and anticipated restructurings;
the loss, modification, or delay of contracts which would, among
other things, adversely impact the Company's recognition of revenue
included in backlog; the Company's dependence on certain industries
and clients; the Company's ability to win new business, manage
growth and costs, and attract and retain employees; the Company's
ability to complete additional acquisitions and to integrate newly
acquired businesses or enter into new lines of business; the impact
on the Company's business of government regulation of the
drug, medical device and biotechnology industry;
consolidation within the pharmaceutical industry and competition
within the biopharmaceutical services industry; the potential for
significant liability to clients and third parties; the potential
adverse impact of health care reform; and the effects of exchange
rate fluctuations and other international economic, political, and
other risks. Such factors and others are discussed more
fully in the section entitled "Risk Factors" of the Company's
Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 as filed with the SEC on
November 8, 2012, which "Risk
Factors" discussion is incorporated by reference in this press
release. The Company specifically disclaims any obligation to
update these forward-looking statements in the future. These
forward-looking statements should not be relied upon as
representing the Company's estimates or views as of any date
subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International
Corporation, and Perceptive Informatics is a trademark of
Perceptive Informatics, Inc. All other names or marks may be
registered trademarks or trademarks of PAREXEL International
Corporation, Perceptive Informatics, Inc. or their respective
owners and are hereby acknowledged.
Contacts:
|
|
Diana
Martin, Vice President Corporate Communications
|
Wing-Kai
Chan, Director
|
PAREXEL
International
|
National
Center of Excellence for Clinical Trial & Research
|
Tel: +1
781 434-5516
|
Tel:+886
2-3366-8246
|
Email:
Diana.Martin@PAREXEL.com
|
Email:
wkchan@ntu.edu.tw
|
|
|
Kim
Leadley
|
|
PAN
Communications
|
|
Tel: +1
617-502-4300
|
Tel: +886
2-23123456 EXT.62020
|
Email:
PAREXEL@pancomm.com
|
Email:
peng@ntuh.gov.tw
|
SOURCE PAREXEL International Corporation